Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Fiche publication
Date publication
octobre 2022
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland
Tous les auteurs :
Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G, Bylicki O, Schott R, Bravard AS, Tiercin M, Lamy R, De Chabot G, Marty A, Moreau D, Locher C, Bernier C, Chouaid C, Descourt R
Lien Pubmed
Résumé
Few data are available on the impact of KRAS mutation in patients with advanced non-squamous non-small cell lung cancer (aNSCLC) treated with immunotherapy. This analysis assessed the impact of KRAS mutation on the efficiency of first-line pembrolizumab immunotherapy in aNSCLC patients with PD-L1 ≥ 50 %.
Mots clés
KRAS mutation, Metastatic disease, Non-small cell lung cancer, Pembrolizumab
Référence
Lung Cancer. 2022 10 26;174:45-49